ARMRA's Sarah Rahal Just Raised $14M. Here Is the Brand Intelligence Behind the Round.

Colostrum is the nutrient-dense first milk produced by mammals in the days following birth. It is loaded with immunoglobulins, growth factors, and bioactive compounds that have been studied for immune function, gut health, and recovery. It is also a deeply unsexy ingredient — at least it was until Sarah Rahal figured out how to market it.

ARMRA — which stands for "Ancestral Restoration of Mucosal Resiliency and Adaptation" — launched in 2021 with a single product: a bovine colostrum powder positioned around cellular health, immunity, and gut barrier restoration. Today, three years later, the brand is at approximately $40M in annual revenue run rate and just closed a $14M Series B.

The Jennifer Aniston Effect: Quantified

In September 2024, Jennifer Aniston posted an Instagram story with an ARMRA tumbler, a glass of water with their colostrum dissolved in it, and the caption "morning ritual." She was not paid. It was organic.

What happened next is one of the clearest case studies in celebrity-adjacent endorsement we have seen in the DTC supplement space. We pulled ARMRA's SimilarWeb traffic data for the 90 days before and after the post:

The spike was real, but what is more remarkable is the retention. Six months after the Aniston post, ARMRA's traffic had settled at approximately 380,000 monthly visits — down from the peak but nearly double the pre-endorsement baseline. This is the hallmark of a brand with genuine product-market fit: a celebrity moment drives awareness, and the product experience keeps a meaningful fraction of those new customers.

The Amazon Halo Effect

One of the most predictable dynamics in DTC supplements is what we call the "Amazon halo": when a brand's DTC brand awareness spikes, Amazon search volume for the brand name follows within 2–4 weeks. Customers who saw the product on social media but prefer to buy on Amazon drive a measurable lift in Amazon revenue.

For ARMRA, we track Amazon monthly revenue at approximately $380,000 in February 2026 — up from roughly $140,000 in July 2024. That is a 171% increase in Amazon revenue over 18 months, closely tracking the DTC traffic trajectory. The Amazon channel now represents approximately 11% of ARMRA's total revenue, which is typical for a premium wellness brand that has not fully invested in Amazon advertising.

What the $14M Is For

ARMRA's previous round was a $5M seed in 2022. The jump to a $14M Series B tells you something about the quality of the business they have built: they were able to scale from $0 to $40M run rate on $5M of venture capital, which implies strong DTC unit economics and minimal retail subsidy.

The new capital has three stated uses:

• Retail expansion: ARMRA is currently in approximately 2,800 Whole Foods, Erewhon, and specialty health locations. The $14M will fund an expansion into Target and potentially a national grocery chain — a move that requires upfront slotting fees, promotional spend, and safety stock that most brands cannot fund from cash flow alone.
• Product line extension: A second SKU is reportedly in development — likely a topical or a colostrum-adjacent supplement that leverages the brand's cellular health positioning.
• Performance marketing: Despite being a DTC brand, ARMRA has kept paid social spend relatively modest — relying heavily on earned media and influencer-organic. The new funding will allow them to test paid at scale for the first time.

The Larger Colostrum Bet

ARMRA is not alone. The colostrum category has gone from a niche ingredient to a mainstream trend in 18 months. Ancestral Supplements, Aloha, and multiple white-label brands have launched colostrum products. The question for ARMRA is whether they can build enough brand equity — and enough distribution — to defend their first-mover position as the category gets crowded.

At $40M run rate with $14M in the bank and a genuine product-market fit signal, they have a real shot.